Clinical Scorecard: CXCR3 Modulates Disease Severity Linked to Neutrophils in SARS-CoV-2 Infection Through the Regulation of CD4+ T Cell Recruitment
At a Glance
Category
Detail
Condition
Key Mechanisms
CXCL9/10/11-CXCR3 signaling regulates immune cell recruitment, particularly T cells, and mitigates neutrophil-driven pathology.
Target Population
Care Setting
Key Highlights
CXCR3 signaling is protective against severe SARS-CoV-2 pathology, particularly through T cell recruitment.
Blocking CXCR3 leads to increased neutrophil infiltration and worsened disease outcomes.
Adoptive transfer of CXCR3+ CD4+ T cells can confer protection in RAG2-/- mice.
CXCL9, CXCL10, and CXCL11 are upregulated in response to SARS-CoV-2 infection.
Neutrophil depletion alleviates disease severity in CXCR3-blocked mice.
Guideline-Based Recommendations
Diagnosis
Management
Consider therapies targeting CXCR3 signaling, such as monoclonal antibodies, to modulate immune response while monitoring for potential adverse effects.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Monoclonal antibodies targeting CXCR3 may worsen outcomes if not carefully managed; consider patient-specific factors.
Clinical Best Practices
Evaluate the balance of T cell and neutrophil responses in COVID-19 patients using flow cytometry and cytokine profiling.
Utilize CXCR3 signaling as a potential therapeutic target in severe cases, considering patient history and immune status.
